Journal•ISSN: 1044-579X
Seminars in Cancer Biology
Elsevier BV
About: Seminars in Cancer Biology is an academic journal published by Elsevier BV. The journal publishes majorly in the area(s): Cancer & Biology. It has an ISSN identifier of 1044-579X. Over the lifetime, 2448 publications have been published receiving 176714 citations. The journal is also known as: Cancer biology.
Topics: Cancer, Biology, Medicine, Carcinogenesis, Cancer cell
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This extract, termed Matrigel, Cultrex, or EHS matrix, promotes cell differentiation, and is used to measure the invasive activity of tumor cells and to improve graft survival, repair damaged tissues, and increase tumor growth.
1,413 citations
•
TL;DR: Experimental and clinical evidence is here assembled in support of the concept that the development of a solid tumor progresses from a prevascular phase to a vascular phase, and indicates that for most tumors, the switch to the angiogenic phenotype depends upon the outcome of a balance betweenAngiogenic stimulators and angiogenesis inhibitors.
1,282 citations
••
TL;DR: The human CEA family comprises 29 genes of which 18 are expressed; 7 belonging to the CEA subgroup and 11 to the pregnancy specific glycoprotein subgroup, which shows a complex expression pattern in normal and cancerous tissues with notably CEA showing a selective epithelial expression.
1,125 citations
••
Tulane University1, Colorado State University2, University of Tübingen3, Applied Science Private University4, Université de Montréal5, United Arab Emirates University6, Rush University Medical Center7, Baylor College of Medicine8, Mount Sinai St. Luke's and Mount Sinai Roosevelt9, Nara Medical University10, National Technical University of Athens11, University of Illinois at Urbana–Champaign12, Creighton University13, Shanmugha Arts, Science, Technology & Research Academy14, University of Rome Tor Vergata15, Purdue University16, Wayne State University17, University of Glasgow18, New York Medical College19, Mayo Clinic20
TL;DR: The advances made toward understanding the basis of cancer immune evasion are discussed, the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection are summarized and some natural agents and phytochemicals merit further study.
1,064 citations
••
TL;DR: Recent findings suggesting that targeting tumour-associated macrophages (TAMs) polarization may represent a novel therapeutic strategy against cancer are discussed.
1,060 citations